Biotech · Public company · Iselin, NJ, US

Outlook Therapeutics, Inc.

Ticker OTLK · SEC CIK 0001649989

Track this companyFree. Adds Outlook Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials41 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

bevacizumabPhase 3 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
bevacizumabPhase 3 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
ranibizumabPhase 3 · Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
ranibizumabPhase 3 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)PHASE3 · COMPLETED · started Jan 24, 2024ClinicalTrials.gov NCT06190093 · fetched Nov 12, 2026
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal DisordersPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 15, 2021ClinicalTrials.gov NCT05112861 · fetched Nov 12, 2026
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal DisordersPHASE3 · COMPLETED · started Oct 1, 2020ClinicalTrials.gov NCT04516278 · fetched Nov 12, 2026
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)PHASE3 · COMPLETED · started Jun 25, 2019ClinicalTrials.gov NCT03834753 · fetched Nov 12, 2026